KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adaptive Biotechnologies (ADPT) Operating Leases (2020 - 2025)

Adaptive Biotechnologies' Operating Leases history spans 6 years, with the latest figure at $70.2 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 11.27% year-over-year to $70.2 million; the TTM value through Dec 2025 reached $70.2 million, down 11.27%, while the annual FY2025 figure was $70.2 million, 11.27% down from the prior year.
  • Operating Leases for Q4 2025 was $70.2 million at Adaptive Biotechnologies, down from $72.4 million in the prior quarter.
  • Across five years, Operating Leases topped out at $108.0 million in Q3 2021 and bottomed at $70.2 million in Q4 2025.
  • The 5-year median for Operating Leases is $93.0 million (2023), against an average of $90.9 million.
  • The largest annual shift saw Operating Leases skyrocketed 160.64% in 2021 before it fell 12.04% in 2025.
  • A 5-year view of Operating Leases shows it stood at $106.7 million in 2021, then fell by 7.42% to $98.8 million in 2022, then fell by 9.5% to $89.4 million in 2023, then fell by 11.46% to $79.1 million in 2024, then fell by 11.27% to $70.2 million in 2025.
  • Per Business Quant, the three most recent readings for ADPT's Operating Leases are $70.2 million (Q4 2025), $72.4 million (Q3 2025), and $74.4 million (Q2 2025).